It showed a significantly longer progression-free and overall survival than conventional platinum doublets in advanced NSCLC (non-small cell lung cancer) with high PD-L1 protein expression in the first-line setting.[1] Although overall safety profile of pembrolizumab appeared to be better, infrequent but severe immune-mediated adverse events (irAEs) occurred in pembrolizumab group. This evidence concerns the gene CD274 and non-small cell lung carcinoma.